No Data
Qianxin Biological-B (02509.HK): The Phase III clinical trial of QX005N for nodular prurigo has successfully completed subject recruitment.
On March 20, Gelonghui announced that on March 19, 2025, the company completed the enrollment of 409 subjects in the PNIII clinical trial of its independently developed QX005N injection (registration number: CTR20241660). This is the first Phase III clinical trial for PN indications conducted by a Chinese company, and it is currently the largest key clinical trial for PN in the Global population.
Chunxin Biological-B (02509.HK): The Chairman of the Board of Directors, Executive Director, and General Manager Qiu Jiwang, along with one of the controlling shareholders, Hangzhou Qunyi Investment, made a voluntary commitment to a lock-up period.
On March 19, Geloong Hui announced that in order to express confidence in the company's long-term value and future prospects, the company's founder, Chairman of the Board of Directors, Executive Director, and General Manager Qiu Jiwan, along with the company's controlling shareholder Hangzhou Quan Yi Investment Management Partnership (General Partnership), voluntarily committed not to sell any of their directly held shares in the company for a period of one year starting from March 20, 2025 (i.e., from March 20, 2025, to March 20, 2026, inclusive of both days), which respectively account for about 4.50% and 18.01% of the company's total issued share capital.
Express News | Qyuns Therapeutics - Founder & Controlling Shareholder Voluntarily Undertaken Not to Sell Any Shares of Co
On March 28, Sansin Biotechnology-B (02509.HK) will hold a Board of Directors meeting to consider and approve the annual performance.
Gelonghui, March 18 – Qunxin Biological-B (02509.HK) announced that the Board of Directors meeting will be held on March 28, 2025 (Friday), in order to consider and approve the group's annual performance for the year ending December 31, 2024, and its release, consider the recommendation for the distribution of a final dividend (if any), and handle Other matters.
QYUNS-B: NOTICE OF BOARD MEETING
Chuangxin Biological-B (02509.HK): The Stock Exchange has granted listing approval for the company's Listed in Hong Kong full circulation.
On March 13, Gelonghui announced that Chuanxin Biopharmaceutical-B (02509.HK) has applied to the Listing Committee of the Stock Exchange for approval to list and trade 17,322,400 shares of Listed in Hong Kong. The company is pleased to announce that the Stock Exchange granted listing approval on March 13, 2025. The listing approval does not indicate that all the necessary approvals for listing the converted Hong Kong shares and all the procedures required for listing have been obtained. The company will publish further announcements on the progress of conversion and listing at the appropriate time in accordance with the listing rules.
